Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy (HCIT-MLD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
High-field MRI and diffusion tensor imaging with 3D reconstruction of the myelin tracks, in combination with multivoxel proton spectroscopy, will allow to precise more accurately the evolution of the white matter lesions in patients affected with Metachromatic Leukodystrophy (particularly in the initial phase of the disease). This will increase the knowledge of the disease and provide new indicators for the selection and evaluation of patients eligible for new therapeutic approaches.
| Condition | Intervention |
|---|---|
|
Late Infantile Metachromatic Leukodystrophy |
Other: High-field MRI (3 Teslas) |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Study of the Natural History of Cerebral White Matter Involvement in Metachromatic Leukodystrophy, Using High-field MRI and Diffusion Tensor Imaging |
- Assess the natural history of the white matter and cortex lesions in MLD using diffusion tensor imaging (DTI)and relaxometry/ high field MRI. [ Time Frame: At inclusion (T0) and 12 months for control. At T0 then at 4, 8, 12 and 18 months for patients ] [ Designated as safety issue: No ]The following parameters will be studied: quantitative measurements of mean diffusivity, longitudinal and transverse fractional anisotropy in ROIs (regions of interest), 3D-tractographic reconstruction of the myelin tracks.
- Assess the natural history of the white matter and cortex lesions in MLD using using multi-voxel spectroscopic imaging. [ Time Frame: At inclusion (T0) and 12 months for control. At T0 then at 4, 8, 12 and 18 months for patients ] [ Designated as safety issue: No ]
- Assess the evolution of cortical atrophy, [ Time Frame: At inclusion (T0) and 12 months for control. At T0 then at 4, 8, 12 and 18 months for patients ] [ Designated as safety issue: No ]
- Correlate the neuroimaging parameters with motor function measure (Gross Motor Function Measure) and cognitive tests (BSID, WPPSI). [ Time Frame: At inclusion (T0) and 12 months for control. At T0 then at 4, 8, 12 and 18 months for patients ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 35 |
| Study Start Date: | November 2010 |
| Estimated Study Completion Date: | May 2015 |
| Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Patients
Patients with a metachromatic leukodystrophy
|
Other: High-field MRI (3 Teslas)
Other Name: High-field MRI (3 Teslas)
|
|
Control
Epileptic population
|
Other: High-field MRI (3 Teslas)
Other Name: High-field MRI (3 Teslas)
|
Detailed Description:
Metachromatic Leukodystrophy (MLD) is a rare autosomal recessive disorder caused by the deficiency of the Arylsulfatase A enzyme (ARSA), resulting in accumulation of galactosyl sulfatide (cerebroside sulfate), a major constituent of the myelin sheath. Accumulation of sulfatides leads to a progressive degeneration of the white matter in the central and peripheral nervous systems (CNS, PNS) and to a neuronal degeneration. The late-infantile form of MLD, which is usually diagnosed in the second year of life, is the most frequent and severe form of the disease. The prognosis is severe, leading to vegetative stage or death within few years after the diagnosis. There is no treatment for patients affected with this early-onset form of the disease.
Conventional MRI (1.5 Tesla) shows extensive involvement of the cerebral white matter (hypo-T1, hyper- T2 and FLAIR signals) indicative of rapidly progressing leukodystrophy. Early cortical atrophy reflects associated neuronal involvement. Proton MR spectroscopy demonstrates abnormalities of choline and N-acetyl-aspartate (demyelination, neuronal loss), which are non-specific but can serve as indicators to monitor the effects of any therapeutic intervention.
In early-onset forms of MLD, conventional MRI becomes abnormal at a relatively advanced stage of the disease and the neuroradiological diagnosis may be difficult before the age of 2 - 2 1/2 years of age. Moreover, topography and extent of detectable lesions are poorly correlated with the disease severity.
In order to improve information provided by neuroimaging, this study aims to investigate prospectively and longitudinally (over a period of 18 months) white and grey matter lesions in 15 MLD children aged 1 to 6 years, using high-field MRI (3 Teslas) and diffusion tensor imaging (DTI) with 3D reconstruction of the myelin tracks. The time interval between diagnosis and inclusion will not exceed 18 months, thus patients will be included at an early stage of their disease. Each time-point (T0, 4 months, 8 months, 12 months and 18 months) will also include neurological evaluation to correlate the imaging, cognitive and motor functions. Children will be included over a period of 2.5 years. The total duration of the study will be 4.5 years. Controls will include 20 age-matched children with cryptogenic partial epilepsy who should have a high-field MRI to detect structural abnormalities. Controls will have a MRI and cognitive evaluation at T0 and 12 months. This study will increase our knowledge of the natural history of MLD and provide new indicators for the selection and evaluation of patients eligible for new therapeutic approaches.
Eligibility| Ages Eligible for Study: | 1 Year to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria (patients):
- Children with proven metachromatic leukodystrophy (MLD) with decreased activity of arylsulfatase A enzyme in leukocytes and abnormal excretion of urinary sulfatides
- Age ≥ 1 year and ≤ 6 years
- Recently diagnosed (within < 18 months)
Inclusion Criteria (control):
- Children with partial cryptogenic epilepsy or with a suspected brain lesion on conventional MRI, who should have high-field MRI to detect structural abnormalities that could benefit from surgical resection
- Age ≥ 1 year and ≤ 6 years
Exclusion Criteria:
- Evolutive heart, pulmonary, renal or gastrointestinal disease
- Contra-indication to sedation
- Contra-indication to MRI (implanted magnetic material)
Contacts and Locations| Contact: Caroline Sevin, MD, PhD | +33 1 45 21 31 12 | caroline.sevin@inserm.fr |
| Contact: Laurence Lecomte, PhD | ++33171196494 | laurence.lecomte@nck.aphp.fr |
| France | |
| Unité de recherche biomédicale, Neurospin, I2BM / DSV / SAC/ CEA, | Recruiting |
| Gif-sur-yvette, France | |
| Contact: Lucie Hertz-Pannier, MD, PhD +33 1 69 08 70 98 lucie.hertz-pannier@cea.fr | |
| Principal Investigator: Lucie Hertz-Pannier, MD, PhD | |
| Service de Neurologie Pédiatrique, Hôpital Bicêtre | Recruiting |
| Paris, France, 94275 | |
| Contact: Caroline Sevin, MD, PhD +33 1 45 21 31 12 caroline.sevin@inserm.fr | |
| Principal Investigator: Caroline Sevin, MD, PhD | |
| Bâtiment Lavoisier - Unité INSERM U 663,Hôpital Necker Enfants Malades | Recruiting |
| Paris, France | |
| Contact: Catherine Chiron, MD, PhD +33 1 42 19 27 00 catherine.chiron@nck.aphp.fr | |
| Principal Investigator: Catherine Chiron, MD, PhD | |
| Principal Investigator: | Caroline Sevin, MD, PhD | Assistance Publique - Hôpitaux de Paris |
More Information
No publications provided
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT01325025 History of Changes |
| Other Study ID Numbers: | P071232 |
| Study First Received: | March 9, 2011 |
| Last Updated: | September 14, 2012 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Metachromatic Leukodystrophy Demyelinating Diseases Magnetic Resonance Imaging Diffusion Tensor Imaging |
Relaxometry Spectroscopy Longitudinal Studies |
Additional relevant MeSH terms:
|
Leukodystrophy, Metachromatic Hereditary Central Nervous System Demyelinating Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Sulfatidosis Sphingolipidoses Lysosomal Storage Diseases, Nervous System |
Leukoencephalopathies Demyelinating Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |
ClinicalTrials.gov processed this record on May 19, 2013